Filtered By:
Condition: Thrombosis
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Papillary Fibroelastoma in Differential Diagnosis of Left Atrial Appendage Masses
We report the cases of 2 patients in whom left atrial appendage masses were initially diagnosed as thrombus. They were treated for embolic stroke and their symptoms resolved; however, their left atrial appendage masses did not regress. After surgery, histologic analysis of the resected masses revealed papillary fibroelastoma in both cases. We discuss the diagnostic and therapeutic dilemmas encountered in patients with papillary fibroelastomas and cardiac masses other than thrombus.PMID:33946109 | DOI:10.14503/THIJ-19-7088
Source: Texas Heart Institute Journal - May 4, 2021 Category: Cardiology Authors: Anthony Alozie Annette Zimpfer Andreas Erbersdobler Felix G Meinel Pascal M Dohmen Alper Öner Source Type: research

Impact of diverse aortic pathologies on outcomes after transapical transcatheter aortic valve replacement
ConclusionIndependent of underlying AP, the TA ‐TAVR is a safe method and shows very promising early and midterm outcomes in patients with various AP.
Source: Journal of Cardiac Surgery - March 30, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Dritan Useini, Blerta Beluli, Hildegard Christ, Justus Strauch Tags: ORIGINAL ARTICLE Source Type: research

New oral anticoagulants versus warfarin in atrial fibrillation after early post-operative period in patients with bioprosthetic aortic valve
CONCLUSIONS: In real-word, NOACs use overcomes the indications provided by guidelines. This study evidenced that NOACs use in patients who developed AF after bioprosthetic AVR was more effective in prevention of thromboembolism and safe in reduction of major bleeding events compared to warfarin.PMID:33744222 | DOI:10.1016/j.athoracsur.2021.03.016
Source: The Annals of Thoracic Surgery - March 21, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Vito A Mannacio Luigi Mannacio Anita Antignano Ciro Mauro Pasquale Mastroroberto Francesco Musumeci Carlo Zebele Gabriele Iannelli Source Type: research

Impact of Mitral Valve Prosthesis on Stroke after Insertion of Veno-Arterial Membrane Oxygenation for Postcardiotomy Shock
This study focused on stroke after valve surgery requiring VA-ECMO.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: S. Ohira, D. Spielvogel, R. Malekan, J.B. Goldberg, P.J. Spencer, S.L. Lansman, M. Kai Tags: 1026 Source Type: research

Two-year outcomes from the PARTNER 3 trial: where do we stand?
Purpose of review The PARTNER 3 trial was conducted to compare outcomes after transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve and surgical aortic valve replacement (SAVR) in individuals at low surgical risk with aortic stenosis. Recently reported rates of death, stoke and valve thrombosis in the TAVR arm have raised concerns about the longevity of this intervention in low-risk individuals. It is incumbent on all members of the Heart Team to understand the potential consequences of these findings. Recent findings TAVR was initially superior to SAVR at 1 year for a primary composite e...
Source: Current Opinion in Cardiology - February 12, 2021 Category: Cardiology Tags: VALVULAR HEART DISEASE: Edited by Subodh Verma and Bobby Yanagawa Source Type: research

Transcatheter aortic valve replacement using the SAPIEN 3 valve versus surgical aortic valve replacement using the rapid deployment INTUITY valve: Midterm outcomes
ConclusionRD ‐SAVR was superior to TA‐/TF‐S3 in the PVL and PPI rates. We observed similar early outcomes and valve hemodynamics. The endocarditis was higher in the TAVR group.
Source: Journal of Cardiac Surgery - January 2, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Dritan Useini, Blerta Beluli, Hildegard Christ, Markus Schl ömicher, Elias Ewais, Peter Haldenwang, Polykarpos Patsalis, Vadim Moustafine, Matthias Bechtel, Justus Strauch Tags: ORIGINAL ARTICLE Source Type: research

Anticoagulation Resumption in a Patient With Mechanical Heart Valves, Antithrombin Deficiency, and Hemorrhagic Transformation Following Thrombectomy After Ischemic Stroke
This study is the first report of administering argatroban and titrating to its appropriate dose in the patient with valve thrombosis, antithrombin deficiency, and HT after mechanical thrombectomy for acute ischemic stroke. Notably, the fluctuations argatroban brings to the coagulation test results might not be interpreted as increased bleeding risk. This case also suggested that the reported timing (day 6 to day 14 after hemorrhage) of anticoagulant resumption in primary intracerebral hemorrhage with mechanical valves might be late for some patients with HT.
Source: Frontiers in Pharmacology - December 16, 2020 Category: Drugs & Pharmacology Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

189 Unexpected, Wanted and Kept: Management of a Pregnancy With Severe LV Dysfunction, Re-Do Mechanical Mitral Valve and Recurrent Arrythmias
We present the multidisciplinary management of a 31YO women with an unexpected pregnancy. Her background included congenital ASD and VSD, surgical repair of PDA and severe aortic coarctation at 2 weeks. Resection of sub-aortic membrane and repair of anterior mitral valve prolapse at 7 years. First mitral valve replacement (MVR) at 16 years of age (tissue valve), second MVR (mechanical) at 27 after presenting with a stroke due to valve thrombosis. LVEF 25% and severely dilated.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: K. Lander, C. O'Brien, D. Watson, R. Yadav Source Type: research

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Safety of thrombolytic therapy in patients with prosthetic heart valve thrombosis who have high international normalized ratio levels
ConclusionsWe concluded that there was no significant difference between PVT patients presenting with subtherapeutic and high INR levels who received thrombolytic treatments regarding both minor and major bleeding complications as well as response to thrombolysis.
Source: Journal of Cardiac Surgery - September 27, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Khadijeh Farzaneh, Seyedeh Hamideh Mortazavi, Alireza Oraii, Kyomars Abbasi, Abbas Salehi Omran, Seyed Hossein Ahmadi Tafti, Ali Bozorgi, Ali Kazemi Saeed, Mojtaba Salarifar, Saeed Sadeghian Tags: ORIGINAL ARTICLE Source Type: research

Bleeding Complications Drive In-Hospital Mortality of Patients with Atrial Fibrillation after Transcatheter Aortic Valve Replacement.
CONCLUSION:  The present study demonstrates that the incidence of bleeding defines the in-hospital outcome of patients with AF after TF-TAVR. Thus, the periprocedural phase demands particular care in bleeding prevention. PMID: 32828074 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 21, 2020 Category: Hematology Authors: Lother A, Kaier K, Ahrens I, Bothe W, Wolf D, Zehender M, Bode C, von Zur Mühlen C, Stachon P Tags: Thromb Haemost Source Type: research

Surgical left atrial appendage occlusion in patients with atrial fibrillation undergoing mechanical heart valve replacement.
CONCLUSIONS: Concomitant SLAAO and MHVR was associated with longer length of stay, and cardiopulmonary bypass time and aortic cross-clamp time, but was not associated with additional protective effects against thromboembolic events and mortality during the 14-month follow-up. PMID: 32826451 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - August 19, 2020 Category: General Medicine Authors: Zheng Y, Rao CF, Chen SP, He L, Hou JF, Zheng Z Tags: Chin Med J (Engl) Source Type: research